What We Do
Byondis engineers differentiated ADCs to overcome cancer’s toughest challenges, combining novel payload platforms, advanced masking technology, and optimized linker strategies to deliver therapies with superior efficacy, safety, and duration of response.
Our Platforms
Our modular ADC platforms are generating potential first and best in class assets, including novel proprietary payloads, advanced masking technologies, and linker and drug conjugation strategies.
Pipeline
Our proprietary pipeline of precision-built ADCs reflects our expertise in research, lead identification, preclinical and clinical development, process development, and manufacturing.
Publications & Presentations
Novel developments are regularly published in highly ranked peer-reviewed journals.
Who We Are
At Byondis, we are dedicated to transforming the lives of those affected by cancer.
Research & Development
Our programs target intractable cancers and autoimmune diseases, with the aim of creating innovative, safe and effective targeted medicines, based on new biological and new chemical entities.
